改善急性移植物抗宿主病的初始治疗
本文综述急性移植物抗宿主病(aGVHD)的危险因素、流行病学与发病机制,讨论从Glucksberg系统到基于生物标志物的风险分层策略的演变,总结支持当前一线治疗的已完成试验,并概述未来方向。
要点
- 糖皮质激素数十年来仍是aGVHD一线治疗的主要手段。
- aGVHD风险分层从Glucksberg系统向基于生物标志物的策略演变。
- 异基因移植数量持续增加,改善aGVHD一线治疗存在巨大未满足需求。
核心结论
- 糖皮质激素数十年来仍是aGVHD一线治疗的主要手段,改善一线治疗存在巨大未满足需求。
研究设计与样本
- 综述,总结支持当前aGVHD一线治疗的已完成试验,并概述未来方向。
主要发现
- aGVHD由供者来源免疫应答针对宿主组织引起,通常累及肝脏、皮肤和胃肠道。
- 由于HLA配型、减低强度预处理和GVHD预防的进步,aGVHD发生率正在下降。
- 风险分层从初始的Glucksberg系统演变至更近期的基于生物标志物的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft versus host disease (aGVHD) is a major complication of hematopoietic stem cell transplantation; it results from donor-derived immune response against host tissues and typically involves the liver, skin and the GI tract. The incidence of acute GVHD is declining due to the advances in HLA typing, reduced intensity conditioning and GVHD prophylaxis. However, corticosteroids remain the mainstay frontline treatment of aGVHD for many decades and as the number of allogeneic transplants continues to increase, there remains a large unmet need to improve frontline treatment for aGVHD. In this review, we outline risk factors, epidemiology and pathogenesis of aGVHD. We discuss the evolving risk stratification, beginning from the initial Gluckesberg system to more recent biomarker-based strategies. We summarize the completed trials that underpin current frontline management and outline future directions.
引用
- Mehta AK, Koreth J. Toward Improving Initial Therapy of Acute Graft Versus Host Disease. Am J Hematol. 2025. PMID: 39936555. doi:10.1002/ajh.27593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。